Home
http://www.virbac.fr/ http://www.boehringer-ingelheim.com/ http://www.novartis.com/ http://www.animalhealth.bayerhealthcare.com/
vetcontact
Vetrinär
Tiermedizin
  WELCOME  
vetcontact
Vetrinär
Tiermedizin
  Privacy Policy  
  Home  
  Login / Newsletter  
vetcontact
Vetrinär
Tiermedizin
  CONTACTS  
vetcontact
Vetrinär
Tiermedizin
  Classifieds  
  New Products  
  VetCompanies  
  VetSchools  
vetcontact
Vetrinär
Tiermedizin
  PROFESSION  
vetcontact
Vetrinär
Tiermedizin
  Edutainment  
  VetAgenda  
  Presentations  
  Posters  
  ESAVS  
  Specialisation  
vetcontact
Vetrinär
Tiermedizin
  INSIGHT  
vetcontact
Vetrinär
Tiermedizin
  Congress News  
  Picture Galleries  
vetcontact
Vetrinär
Tiermedizin
  PRODUCTS  
vetcontact
Vetrinär
Tiermedizin
  Bayer  
  Boehringer Ing.  
  Novartis  
  Virbac

 
  Simply book for less...  
    

Bovine    Equine    Small Animal Practice    Swine Practice    Articles    Vetjournal    
deutsch english español polski francais
Home / WELCOME / Archiv / Small Animal Practice /     
 
Prednisolone plus radiotherapy for canine mast cell tumours
Mast cell tumours are common neoplasias in dogs. If possible, surgery is the therapy of choice, often followed by chemotherapy. But what if the mast cell tumours are non-resectable and classified as grade III? Is the combination of prednisolone and radiotherapy superior to other therapies?

This retrospective study describes 35 dogs with non-resectable, grade IIII mast cell tumours on the head or limb treated with prednisolone (40 mg m2 daily) for 1014 days prior to radiotherapy (4 800 cGy fractions at 7-day intervals) from a 4 MV linear accelerator.

Prednisolone was continued at a reduced dose rate (20 mg m2) during radiotherapy and for 2 months or longer afterwards.

Eighteen of 24 tumours (75%) decreased in size in response to prednisolone treatment.
By 68 weeks following radiotherapy, 12 dogs had achieved a complete remission and 19 a partial response.
Two tumours remained static and two progressed during the course of treatment.

The overall response rate was 88.5%. With long-term follow-up, 11 dogs experienced local recurrence (n = 4), metastasis (n = 5) or both (n = 2).

The median progression-free interval was 1031 days (95% CI 277.441784.56, KaplanMeier), with 1- and 2-year progression-free rates of 60 and 52%, respectively.

Tumour grade did not predict the prognosis for this group of dogs, but tumour location did affect the outcome.
Dogs with tumours located on the limb survived longer than those with tumours on the head. The combination of prednisolone with radiotherapy appears to have a useful role in the management of measurable mast cell tumours sited on the head and distal extremities.


Source: Dobson, J., Cohen, S. & Gould, S. (2004)
Treatment of canine mast cell tumours with prednisolone and radiotherapy. In: Veterinary and Comparative Oncology 2 (3), 132-141.




Tell a friend   |   Print version   |   Send this article

SMALL ANIMAL PRACTICE

Proteasome inhibitors for canine and human osteosarcomamembers
Osteosarcoma, a common malignancy in large dog breeds, typically metastasises from long bones to lungs and is usually fatal within 1 to 2 years of diagnosis. Better therapies are needed for canine patients and their human counterparts, a third of whom die within 5 years of diagnosis. The authors compared the in vitro sensitivity of canine osteosarcoma cells derived from 4 tumours to the currently used chemotherapy drugs doxorubicin and carboplatin, and 4 new anti‐cancer drugs.

  • Pharmacokinetics of a novel mirtazapine transdermal ointment in catsmembers
  • Bacterial contamination in 50% dextrose vials after multiple puncturesmembers
  • Sotalol and the ventricular systolic function in dogs with ventricular arrhythmiasmembers
  • Life-threatening arterial haemorrhage during nephrectomymembers
  • Update to the chinchilla retinamembers
  • Vocal fold granulomas in brachycephalic dogsmembers
  • Extracellular vesicles in mammary cancer of dogs and catsmembers
  • Immunocytochemical assay using aqueous humor to diagnose feline infectious peritonitis members
  • Microbiota of traumatic, open fracture wounds and the mechanism of injury members
  • False-positive CT and radiography results for bronchial collapse in healthy dogsmembers
  • Variability of SDMA in apparently healthy dogsmembers
  • Bioavailability of suppository acetaminophen in dogsmembers


  • [ Home ] [ About ] [ Contact / Request ] [ Privacy Policy ]

    Copyright © 2001-2018 VetContact GmbH
    All rights reserved